Hikma Pharmaceuticals Plc Injectables Analyst and Investor Day USA (4549O)
October 11 2012 - 8:00AM
UK Regulatory
TIDMHIK
RNS Number : 4549O
Hikma Pharmaceuticals Plc
11 October 2012
Hikma Injectables Analyst and Investor Day
London, 11 October 2012- Hikma Pharmaceuticals PLC (LSE: HIK)
(NASDAQ Dubai: HIK), the fast growing multinational pharmaceutical
group, is today hosting a site visit for analysts and investors in
Cherry Hill, New Jersey. The visit will include a tour of its
recently acquired Multi-Source Injectables ("MSI") manufacturing
facility and management will be giving a series of presentations on
Hikma's global Injectables business.
In the year to date, Hikma's Injectables business has delivered
strong organic growth across the US, Europe and the MENA region.
This performance has been driven by new product launches, increased
tender sales, better portfolio management, new contract wins, more
efficient manufacturing and increased demand from continuing
product shortages in the US. In August, Hikma announced a 94%
increase in revenues to $225.2 million and adjusted EBIT margin of
22.0% for the six months ended 30 June 2012. At this time, the
company stated that the first half performance was expected to be
sustained in the second half of the year. Hikma reiterates this
view and continues to see strong potential for its global
Injectables business in the coming years.
Said Darwazah, Chief Executive Officer of Hikma, said: "We are
delighted with the performance of our global Injectables business,
which has been transformed by the acquisition of MSI. Our track
record of investing in our high quality manufacturing facilities
and product portfolio is helping to drive the excellent growth seen
so far this year and we remain very optimistic about the prospects
for our global Injectables business both in the short and longer
term."
A live webcast and presentation slides will be available at 9am
EST / 2pm GMT on Hikma's website. Please follow this link to view
the event:
http://www.hikma.com/en/investors/analyst-investor-day.aspx
-- ENDS --
Enquiries:
Hikma Pharmaceuticals PLC
Susan Ringdal
Vice President, Corporate Strategy +44 (0)20
and Investor Relations 7399 2760
FTI Consulting Ben Atwell/Julia Phillips/Jonathan
Birt/Matthew Cole +44 (0)20 7831 3113
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma operates through three businesses: "Branded", "Injectables"
and "Generics", based principally in the Middle East and North
Africa ("MENA"), where it is a market leader, the United States and
Europe. In 2011, Hikma achieved revenues of $918.0 million and
profit attributable to shareholders of $80.1 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCMBBTTMBJBMJT
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024